Brian C. Jensen

This study shows trametinib causes mitochondrial injury and innate immune activation in mouse hearts, leading to cardiomyopathy and heart failure.

The paper uses proteomic kinome profiling and machine learning to predict kinase inhibitor cardiotoxicity by analyzing off-target kinase engagement and its association with cardiac adverse events.

The paper identifies genetic loci associated with heart failure susceptibility and response in mice, highlighting candidate genes that modulate cardiac hypertrophy.

This study identifies ROR-alpha as a critical regulator of the cardiomyocyte transcriptome, including the alpha-1A adrenergic receptor, through genetic and pharmacologic analyses in mice.

This study develops NanoDMX, a liposomal formulation of DMX-5804, which prevents doxorubicin-induced left ventricular dysfunction in mice and protects cardiomyocytes through non-JNK pathways.

This paper develops HiA Zippersomes to enhance EV accumulation and retention in the infarcted myocardium, improving cardiac function and reducing infarct size.

This study shows that RORα regulates mitophagy via caveolin-3 in cardiomyocytes, preserving mitochondrial function and preventing cardiac hypertrophy.